Early prediction of immune checkpoint inhibitor treatment efficacy in patients with untreated advanced non-small-cell lung cancer
Not Applicable
Recruiting
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-jRCT1011200014
- Lead Sponsor
- Takeuchi Satoshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
1. Previously untreated with chemotherapy
2. Patients more than 20 years old
3. Treated with pembrolizumab (combined with or without chemotherapy)
4. Appropriate physical status
5. Obtained informed consent
Exclusion Criteria
1. Small-cell carcinoma or unknown
2. Positive for EGFR mutation, ALK fusion, Ros-1 fusion, and BRAF mutation
3. Ever treated with chemotherapy or radiotherapy
4. Poor physical status
5. Severe complication
6. Fasting blood glucose over 150 mg/dl
7. Unable to perform 18F-FDG PET/CT or CT because of complications
8. Other inappropriate patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the discriminative power of the change of SUVmax, which is obtained via PET/CT 6 week after the initiation of pembrolizumab treatment.
- Secondary Outcome Measures
Name Time Method same analysis using liquid biopsy.